Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression
Journal of Clinical Investigation · 03.07.2023 · 133 (13)
DOI: 10.1172/jci161713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.07.2023. Verfasst von Dongmei Gou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China National Natural Science Foundation, the 111 Project, the Natural Science Foundation Project of Chongqing.
Abstract (Originalsprache)
Deciphering the crosstalk between metabolic reprogramming and epigenetic regulation is a promising strategy for cancer therapy. In this study, we discovered that the gluconeogenic enzyme PCK1 fueled the generation of S-adenosylmethionine (SAM) through the serine synthesis pathway. The methyltransferase SUV39H1 catalyzed SAM, which served as a methyl donor to support H3K9me3 modification, leading to the suppression of the oncogene S100A11. Mechanistically, PCK1 deficiency-induced oncogenic activation of S100A11 was due to its interaction with AKT1, which upregulated PI3K/AKT signaling. Intriguingly, the progression of hepatocellular carcinoma (HCC) driven by PCK1 deficiency was suppressed by SAM supplement or S100A11 KO in vivo and in vitro. These findings reveal the availability of the key metabolite SAM as a bridge connecting the gluconeogenic enzyme PCK1 and H3K9 trimethylation in attenuating HCC progression, thus suggesting a potential therapeutic strategy against HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital.
- Institute of Life Sciences, and.
- Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Förderung
- China National Natural Science Foundation
- the 111 Project
- the Natural Science Foundation Project of Chongqing
- the Science and Technology Research Program of Chongqing Municipal Education Commission
- he Future Medical Youth Innovation Team of Chongqing Medical University
- Talent Development Program of CQMU for Postgraduate
Zitieren
APA
Gou, D., Liu, R., Shan, X., Deng, H., Chen, C., Xiang, J., Liu, Y., Gao, Q., Li, Z., Huang, A., Wang, K., & Tang, N. (2023). Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. Journal of Clinical Investigation, 133(13). https://doi.org/10.1172/jci161713
Vancouver
Gou D, Liu R, Shan X, Deng H, Chen C, Xiang J, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. Journal of Clinical Investigation. 2023;133(13). doi:10.1172/jci161713
BibTeX
@article{Gou2023,
author = {Gou, Dongmei and Liu, Rui and Shan, Xiaoqun and Deng, Haijun and Chen, Chang and Xiang, Jin and Liu, Yi and Gao, Qingzhu and Li, Zhi and Huang, Ailong and Wang, Kai and Tang, Ni},
title = {Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {13},
doi = {10.1172/jci161713}
}
EUVIMED